QPX2014 + QPX7728

QPX2014 + QPX7728 is an intravenous fixed-combination antibiotic currently under clinical development for the treatment of serious infections caused by drug-resistant gram-negative bacteria, specifically targeting multidrug-resistant strains of Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. QPX2014 is a β-lactam antibacterial (structure and class undisclosed), while QPX7728—also known as xeruborbactam—is a novel, ultra-broad-spectrum β-lactamase inhibitor of the cyclic boronate class. QPX7728 inhibits both serine and metallo-β-lactamases (Classes A, B, C, D), including enzymes that confer resistance to cephalosporins and carbapenems. The mechanism involves QPX2014 exerting antibacterial action, potentiated by QPX7728, which neutralizes β-lactamase enzymes through covalent reversible inhibition (serine β-lactamases) and competitive, reversible inhibition (metallo-β-lactamases) thus protecting QPX2014 from enzymatic degradation[1][3][4][5]. Developed to address the global threat posed by multidrug-resistant organisms, this combination exhibits potent activity against strains resistant to other current β-lactam/β-lactamase inhibitor therapies[1][4].

Brand names

OMNIvance

Other names

xeruborbactam + QPX2014